News coverage about Cambrex (NYSE:CBM) has been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Cambrex earned a news impact score of 0.22 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 48.3517515920716 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media stories that may have impacted Accern Sentiment’s rankings:
- Cambrex Co. (CBM) Receives Average Rating of “Hold” from Brokerages (americanbankingnews.com)
- Cambrex to Present at the 2018 RBC Capital Markets Global Healthcare Conference (finance.yahoo.com)
- Cambrex (CBM) Downgraded by Longbow Research (americanbankingnews.com)
- First Analysis Weighs in on Cambrex Co.’s Q3 2018 Earnings (CBM) (americanbankingnews.com)
Shares of Cambrex (NYSE CBM) opened at $52.80 on Friday. The stock has a market cap of $1,734.32, a PE ratio of 17.20, a PEG ratio of 1.28 and a beta of 2.38. Cambrex has a fifty-two week low of $42.55 and a fifty-two week high of $62.95.
Cambrex (NYSE:CBM) last issued its earnings results on Thursday, February 8th. The biotechnology company reported $1.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.10 by $0.17. The company had revenue of $182.28 million for the quarter, compared to analysts’ expectations of $181.39 million. Cambrex had a net margin of 19.17% and a return on equity of 22.42%. Cambrex’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.23 EPS. equities analysts predict that Cambrex will post 2.76 EPS for the current year.
Several equities research analysts have commented on the stock. Longbow Research cut shares of Cambrex from a “buy” rating to a “neutral” rating in a research report on Wednesday. William Blair initiated coverage on shares of Cambrex in a report on Tuesday, January 16th. They issued an “outperform” rating on the stock. Zacks Investment Research raised shares of Cambrex from a “strong sell” rating to a “hold” rating in a report on Monday, January 15th. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $60.00 target price (down from $70.00) on shares of Cambrex in a report on Tuesday, October 31st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company’s stock. Cambrex has an average rating of “Hold” and a consensus price target of $60.00.
ILLEGAL ACTIVITY WARNING: “Cambrex (CBM) Getting Somewhat Favorable Media Coverage, Study Finds” was originally posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.thelincolnianonline.com/2018/02/18/cambrex-cbm-getting-somewhat-favorable-media-coverage-study-finds.html.
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.